Page reviewed Aug 23, 2026 · from FDA-approved labeling (Drugs@FDA) — no drug-specific Medicare LCD
Quick answer
Medicare benefit
Part B (physician-administered)
FDA-indicated diagnoses
9 ICD-10 codes
Governing policy
FDA indications (no LCD)
Contractor (MAC)
Per medical necessity
Source
FDA labeling
Page reviewed
Aug 23, 2026
HCPCS codes covered:
J0491
J0491
No drug-specific Medicare coverage article exists for Saphnelo. Coverage is decided per medical necessity by your MAC. The FDA-approved indications below are the labeled uses Medicare generally pays for; an off-label use may be covered if supported by an approved compendium. Find your MAC by state →
What Medicare pays for Saphnelo (2026 Q4)
2026 Q4 payment limit per billing unit for Saphnelo’s HCPCS code (how ASP + 6% works):
| HCPCS | Description | Per unit | Allowed (ASP + 6%) |
|---|---|---|---|
| J0491 | Inj anifrolumab-fnia 1mg | 1 mg | $18.461 |
CMS ASP Drug Pricing File, 2026 Q4. Saphnelo patient out-of-pocket estimate →
Worked billing example for Saphnelo
A concrete, paste-checkable example using J0491’s own billing-unit basis and vial sizes — not a hypothetical.
| Scenario | 300 mg fixed IV dose, every 4 weeks |
| Dose administered | 300 mg |
| Billing unit basis | 1 unit = 1 mg |
| Billing units (dose ÷ unit basis, rounded up) | 300 units of J0491 |
| Vial combination drawn (min-waste plan) | 1 × 300 mg vial |
| Discarded (waste) | None |
| Wastage modifier (JW / JZ) | Bill all 300 units on a single line with JZ (attests zero drug discarded). JW vs JZ, with examples → |
| Medicare allowable (ASP + 6%, 2026 Q4) | 300 units × $18.461/unit = $5538.30 |
Allowable, not paid: sequestration and the covered diagnosis still apply.
Dose source: drugs/saphnelo.html — "Adult dosing: 300 mg IV q4wk — fixed dose, NOT weight-based.". Different dose or drug? Compute your own dose → or estimate the full cost & patient out-of-pocket →.
Saphnelo (HCPCS J0491) is paid under Part B only when the claim’s ICD-10 code is one the MAC accepts; otherwise expect a CO-50 denial. How Part B drug coverage is decided →
Covered ICD-10 diagnoses for Saphnelo
The 9 FDA-approved indications for J0491, grouped by condition — filter to find a code.
Systemic Lupus Erythematosus — 4 diagnoses (applies to J0491)
Diseases of the musculoskeletal system & connective tissue (4)
| ICD-10 | Covered diagnosis |
|---|---|
| M32.10 | SLE, organ or system involvement unspecified |
| M32.13 | Lung involvement in SLE |
| M32.19 | Other organ or system involvement in SLE |
| M32.9 | SLE, unspecified |
Lupus Nephritis — 2 diagnoses (applies to J0491)
Diseases of the musculoskeletal system & connective tissue (2)
| ICD-10 | Covered diagnosis |
|---|---|
| M32.14 | Glomerular disease in SLE |
| M32.15 | Tubulo-interstitial nephropathy in systemic lupus erythematosus |
SLE — 3 diagnoses (applies to J0491)
Diseases of the musculoskeletal system & connective tissue (3)
| ICD-10 | Covered diagnosis |
|---|---|
| M32.11 | Endocarditis in systemic lupus erythematosus |
| M32.12 | Pericarditis in systemic lupus erythematosus |
| M32.8 | Other forms of systemic lupus erythematosus |
What commercial payers require for Saphnelo
Medicare Part B is only half the answer — most Saphnelo claims are adjudicated by a commercial plan with its own medical policy. Below is what 26 commercial payers publish for Saphnelo, read from each payer's own policy document. 23 of 23 that state a position require prior authorization (3 do not say clearly, so confirm those on the call), and 11 run a site-of-care program that can push the infusion out of the hospital outpatient setting.
| Payer | Prior auth | Preferred product first | Site of care | Indications named | Policy date |
|---|---|---|---|---|---|
| Aetna policy ↗ | Required | — | Site of Care Utilization Management Policy applies. | 1 | 2026-06-05 |
| Anthem / Elevance policy ↗ | Required | — | — | 1 | 2022-08-19 |
| Arkansas BCBS policy ↗ | Required | — | Site-of-care program applies | 1 | 2026-08-19 |
| BCBS Federal Employee Program policy ↗ | Required | — | — | 1 | 2026-04-01 |
| BCBS Kansas policy ↗ | Required | — | — | 1 | 2025-04-07 |
| BCBS Louisiana policy ↗ | Not stated — confirm on the call | — | — | 1 | 2025-12-01 |
| BCBS Michigan policy ↗ | Required | — | Site-of-care program applies | 1 | 2025-10-09 |
| BCBS Minnesota policy ↗ | Required | — | — | 1 | 2025-04-07 |
| BCBS Nebraska policy ↗ | Required | — | — | 1 | 2025-11-05 |
| BCBS South Carolina policy ↗ | Required | — | Site-of-care program applies | — | 2026-01-01 |
| BCBS Tennessee policy ↗ | Required | — | — | 1 | 2025-09-30 |
| Blue Shield of California policy ↗ | Required | — | required to have their medication administered at a preferred site of service | 1 | 2026-07-01 |
| Capital BlueCross policy ↗ | Required | — | — | 1 | 2025-04-07 |
| CareFirst BCBS policy ↗ | Required | — | Site-of-care program applies | 1 | — |
| Centene / Ambetter policy ↗ | Required | — | — | 1 | 2021-12-01 |
| Cigna policy ↗ | Required | — | — | 1 | 2026-06-01 |
| Excellus BCBS policy ↗ | Required | — | — | 1 | 2026-06-01 |
| Florida Blue policy ↗ | Required | — | — | 1 | 2026-07-01 |
| HCSC (IL/TX/OK/NM/MT) policy ↗ | Required | — | BCBS lists Saphnelo (J0491) for Infusion Site of Care review: the payer reviews the medical need for the drug AND the place of infusion. Confirm the infusion site is approved with the prior authorization. | 1 | 2026-04-01 |
| Highmark BCBS policy ↗ | Required | — | Outpatient site of care; inpatient only in special circumstances | 1 | 2022-03-06 |
| HMSA (BCBS Hawaii) policy ↗ | Required | — | — | — | 2026-06-12 |
| Independence Blue Cross policy ↗ | Not stated — confirm on the call | — | — | 1 | 2024-06-17 |
| Premera Blue Cross policy ↗ | Not stated — confirm on the call | — | subject to review for site of service administration | 1 | 2026-07-02 |
| Regence BCBS policy ↗ | Required | — | site of care administration requirements must be met per dru408 | 1 | 2026-06-01 |
| UnitedHealthcare policy ↗ | Required | — | Saphnelo is on UnitedHealthcare's Provider Administered Drugs – Site of Care list (updated 10/01/2026). An infusion in a hospital outpatient department (place of service 19 or 22) has to meet that policy's criteria; a physician office, home infusion or ambulatory infusion suite is an accepted alternative. | 1 | 2026-07-01 |
| Wellmark BCBS policy ↗ | Required | — | — | 1 | 2025-06-07 |
What Saphnelo payers put in writing
Quoted from the medical policies linked above — 29 distinct requirements across 26 payers. These are the sentences an appeal has to answer.
Clinical prerequisites — what must be true before they pay
Member is using Saphnelo in combination with other biologics.
— Aetna, BCBS Tennessee and 2 other payers policy ↗Prescribed by or in consultation with a rheumatologist
— Blue Shield of California, Centene / Ambetter, UnitedHealthcare policy ↗This medication must be prescribed by or in consultation with a rheumatologist or a specialist in the treatment of systemic lupus erythematosus.
— Aetna, CareFirst BCBS policy ↗Individual is using in combination with standard therapy (for example, corticosteroids, antimalarials, and/or immunosuppressants [but not other biologics or cyclophosphamide])
— Anthem / Elevance, Arkansas BCBS policy ↗Patient is > 18 years of age
— BCBS Louisiana, Cigna policy ↗Individual’s SLE disease remains active while on corticosteroids, antimalarials, or immunosuppressants (alone or as combination therapy) for at least the last 30 days
— Anthem / Elevance policy ↗
Prior authorization
Precertification of anifrolumab-fnia (Saphnelo) is required of all Aetna participating providers and members in applicable plan designs.
— Aetna policy ↗Prior Approval is required for Anifrolumab-fnia.
— Arkansas BCBS policy ↗J0491 Infusion Site of Care, Provider Administered Drug Therapy Injection Anifrolumab-Fnia 1 Mg BCBSTX
— HCSC (IL/TX/OK/NM/MT) policy ↗Coverage will be provided for 12 months (365 days) and may be renewed.
— BCBS Kansas policy ↗Line of Business PA Required in Medical Management System (Yes/No) BCBS Yes BCN Yes MAPPO Yes BCNA Yes
— BCBS Michigan policy ↗Line of Business PA Required in Medical Management System (Yes/No) BCBS Yes
— BCBS Michigan policy ↗
Quantity and frequency limits
300 billable units (300 mg) every 4 weeks
— BCBS Kansas, Capital BlueCross policy ↗300 mg/2 mL vial 1 vial per 28 days
— Anthem / Elevance policy ↗IV: 300 mg (1 vial) every 4 weeks
— Centene / Ambetter policy ↗1 vial (300 mg) per 28 days
— Wellmark BCBS policy ↗
Dosing rules
300 mg as an intravenous infusion over a 30-minute
— Aetna policy ↗Dose does not exceed 300 mg every 4 weeks
— Florida Blue policy ↗300 billable units (300 mg) every 4 weeks
— BCBS Minnesota policy ↗Approve 300 mg given as an intravenous infusion administered not more frequently than once every 4 weeks.
— Cigna policy ↗The recommended dosage is 300mg intravenous infusion every 4 weeks
— Independence Blue Cross policy ↗
Reauthorization / continuation
Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition.
— CareFirst BCBS policy ↗The drug will be initially approved for 3 months.
— HMSA (BCBS Hawaii) policy ↗
Site-of-care restrictions
Site of Care Utilization Management Policy applies.
— Aetna policy ↗J0491 Infusion Site of Care, Provider Administered Drug Therapy Injection Anifrolumab-Fnia 1 Mg BCBSTX
— HCSC (IL/TX/OK/NM/MT) policy ↗The drugs listed below require prior authorization AND may only be authorized to be administered in certain locations (sites of care), such as an infusion center or the patient’s home. Note that the site-of-care requirement does not apply if the drug is being used for cancer treatment.
— BCBS South Carolina policy ↗This policy provides coverage for administration of Saphnelo in an outpatient hospital setting for up to 45 days when a member is new to therapy or reinitiating therapy after not being on therapy for at least 6 months.
— CareFirst BCBS policy ↗Anifrolumab-fnia (Saphnelo) is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances
— Highmark BCBS policy ↗Saphnelo (anifrolumab-fnia) IV is subject to review for site of service administration.
— Premera Blue Cross policy ↗
Read from each payer's published medical policy between 2026-08-03 and 2026-08-13. Every requirement above is quoted from the policy it links to. Commercial policy changes without notice — confirm before you bill.
How to bill Saphnelo
Put a medically necessary, FDA-indicated diagnosis from the list above on the claim line with J0491. Matching codes, units and JZ/JW wastage →
Which policy governs Saphnelo
No drug-specific LCD or Article — see the note at the top of this page. Find your MAC → What an LCD, an Article and an NCD each govern →
If a claim for Saphnelo is denied
With no drug-specific Article, the usual cause is a diagnosis the MAC does not accept as medically necessary for J0491, or an off-label use with no compendium support. The five denial patterns and how to fix each →
Frequently asked questions
- Is Saphnelo covered by Medicare?
- Yes. Saphnelo (J0491) is covered under Medicare Part B as a physician-administered drug when billed for a medically necessary indication. There is no drug-specific Local Coverage Determination (LCD) for it, so coverage is determined per medical necessity by your MAC; the FDA-approved indications below are the starting point. None of the 8 Medicare Administrative Contractors lists J0491 as self-administered.
- What diagnoses are covered for Saphnelo (J0491)?
- Medicare publishes no drug-specific covered-diagnosis list for J0491. The 9 ICD-10 codes here are the FDA-approved indications; an off-label use needs approved-compendium support (DrugDex, NCCN) to be payable.
- Which Medicare policy covers Saphnelo?
- No drug-specific LCD or Billing & Coding Article exists for Saphnelo. It's covered under the general Medicare Part B drug benefit per medical necessity, as judged by your Medicare Administrative Contractor (MAC).
- Why was my Saphnelo claim denied as not medically necessary?
- The most common cause is a diagnosis the MAC doesn't consider medically necessary for J0491. Bill a covered/FDA-approved indication from the list below, document medical necessity, and confirm any local guidance with your MAC.
Related references
Covered is only half the answer.
You know the diagnosis is payable. Now quote the patient before the visit and catch underpayments: get Saphnelo's exact Medicare allowed amount, your payer's rate vs. ASP+6%, and the patient's out-of-pocket — in about 30 seconds, free.
Estimate Saphnelo cost & patient owe →Source & verification
- Source
- FDA-approved indications (Drugs@FDA labeling) mapped to ICD-10-CM. No drug-specific Medicare LCD/Article exists for Saphnelo — Part B coverage is determined per medical necessity by your MAC.
- Primary sources
- DailyMed — Saphnelo prescribing information · CMS Part B Drug ASP Pricing File — the quarterly payment limit quoted above · CMS Medicare Coverage Database — searched for “Saphnelo”; no drug-specific NCD, LCD or Billing & Coding Article exists, which is why the FDA-indicated codes above are the working list
- Page last reviewed by CareCost
- Aug 23, 2026 (coverage data retrieved 2026-09-21; we re-verify against CMS quarterly).
- Notes
- ICD-10-CM is public domain; CPT® (AMA) is intentionally not listed. Reference, not billing advice — built from the CMS Coverage API per our methodology; corrections to editorial@carecostestimate.com.